BLRX is BioLineRX Ltd — a non-dividend-paying stock. Trading at $2.74. Market cap: $13M.
Stock snapshot
| Price | $2.74 |
| Market cap | $13M |
| Sector | — |
| Exchange | XNAS |
| Pays dividend | No |
About BLRX
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Frequently asked
What is BLRX's current stock price?
BLRX (BioLineRX Ltd) is currently trading at $2.74.
Does BLRX pay a dividend?
BLRX (BioLineRX Ltd) does not currently pay a regular dividend.
Track BLRX in DiviDrip
Add BLRX to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search BLRX and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.